We are live on ! Find out more
LPC

Lion Point Capital Portfolio holdings

AUM $16.7M
1-Year Est. Return 119.35%
This Fund
S&P 500
This Quarter Est. Return
+44.85%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$19.3M
AUM Growth
+$1.72M
Cap. Flow
+$309
Cap. Flow %
0%
Top 10 Hldgs %
48.51%
Holding
42
New
15
Increased
6
Reduced
10
Closed
3

Top Buys

Rank Stock Value
1
CUE icon
Cue Biopharma
CUE
+$1.35M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$601K
3
HUMA icon
Humacyte
HUMA
+$590K
4
QURE icon
uniQure
QURE
+$567K
5
JANX icon
Janux Therapeutics
JANX
+$447K

Top Sells

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$1.14M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$912K
3
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$909K
4
INSM icon
Insmed
INSM
+$900K
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$769K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
26
uniQure
QURE
$3.03B
$352K 1.82%
+14,700
New +$567K
PCRX icon
27
Pacira BioSciences
PCRX
$1.04B
$349K 1.81%
+13,500
New +$321K
VTRS icon
28
Viatris
VTRS
$20.4B
$345K 1.78%
+27,700
New +$299K
AZTA icon
29
Azenta
AZTA
$1.3B
$323K 1.67%
+9,700
New +$317K
RCKT icon
30
Rocket Pharmaceuticals
RCKT
$340M
$302K 1.56%
86,000
– –
JANX icon
31
Janux Therapeutics
JANX
$925M
$262K 1.36%
+19,000
New +$447K
EWTX icon
32
Edgewise Therapeutics
EWTX
$4.13B
$226K 1.17%
+9,100
New +$183K
INVA icon
33
Innoviva
INVA
$1.55B
$164K 0.85%
+8,200
New +$160K
ARQT icon
34
Arcutis Biotherapeutics
ARQT
$3.36B
$152K 0.79%
5,250
-30,050
-85% -$769K
IPHA
35
Innate Pharma
IPHA
$164M
$142K 0.73%
+81,151
New +$157K
NERV icon
36
Minerva Neurosciences
NERV
$185M
$141K 0.73%
+35,000
New +$130K
GHRS icon
37
GH Research
GHRS
$1.93B
$130K 0.67%
+10,200
New +$139K
SPRB
38
Spruce Biosciences
SPRB
$118M
$87.1K 0.45%
1,000
– –
MRSN
39
DELISTED
Mersana Therapeutics
MRSN
$2.89K 0.02%
100
-25,660
-100% -$487K
AVDL
40
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-59,700
Closed -$912K
INSM icon
41
Insmed
INSM
$21.4B
– –
-6,250
Closed -$900K
KNSA icon
42
Kiniksa Pharmaceuticals
KNSA
$5.8B
– –
-23,400
Closed -$909K
1
2

Similar funds

PA
PPM America Chicago, Illinois $16.6M AUM 31.99% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
SRA
Summit Rock Advisors New York $16M AUM
CP
Covalent Partners Concord, Massachusetts $17.6M AUM 2.91% 1-Year Est. Return
B
BP London, United Kingdom $17.7M AUM 12.34% 1-Year Est. Return
BCPE
Bain Capital Public Equity Boston, Massachusetts $18M AUM 35.19% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $18.1M AUM 29.08% 1-Year Est. Return

Lion Point Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Lion Point Capital held 42 positions worth $19.3M, up 9.8% from $17.6M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Lion Point Capital's Q4 2025 filing shows 15 new, 6 increased, 10 reduced and 3 closed positions. Its largest new stake was Cue Biopharma: 73,428 shares worth $673K. The largest sale was Mineralys Therapeutics, an estimated $1.14M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Lion Point Capital's largest Q4 2025 buy was Cue Biopharma: 73,428 shares worth $673K.
  • Lion Point Capital added most to Humacyte in Q4 2025, an estimated $590K increase.
  • Lion Point Capital's biggest Q4 2025 reduction was Mineralys Therapeutics, cutting an estimated $1.14M.
  • Lion Point Capital fully exited Avadel Pharmaceuticals in Q4 2025, selling an estimated $912K.
  • Lion Point Capital's ten largest holdings make up 49% of its $19.3M portfolio in Q4 2025.
  • Lion Point Capital opened 15 new positions and closed 3 in Q4 2025.
  • Lion Point Capital's portfolio value rose 9.8% quarter-over-quarter to $19.3M.

Based on Lion Point Capital's 13F filing for Q4 2025, filed 17 Feb 2026.